Dr. Ferrari is the President, CEO, and Board Chair of BrYet US, Inc. in Houston, Texas; and he serves as Board Chair of BrYet Europe, a wholly owned subsidiary of BrYet US, based in Italy. He is also an Affiliate Professor of Pharmaceutics at the University of Washington in Seattle, Washington.

From 2010 to 2019, Dr. Ferrari served in several different capacities at the Houston Methodist Hospital, including President and CEO of The Houston Methodist Hospital Research Institute (TMHRI), Executive VP of Houston Methodist Hospital, and Senior Associate Dean of the hospital’s academic affiliate, Weill Cornell Medical College in New York.

Dr. Ferrari has had several tenured academic positions in bioengineering/medicine as well. He was a Professor at his graduate Alma Mater UC Berkeley, Ohio State University, MD Anderson Cancer Center, and he was an Adjunct Professor at Rice University. At the University of Texas Health Science Center, he was both Professor and Chair of The Department of Nanomedicine and Biomedical Engineering.

An internationally recognized expert in cancer therapeutics, nanomedicine, and biomedical nanotechnology, he served as Special Expert on Nanotechnology and Eminent Scholar at The National Cancer Institute from 2003-2005.

Having earned a Phd (Dottore) in Mathematics from the Universita’ di Padova, Italy, he went on to receive an MSc and PhD in mechanical engineering from University of California, Berkeley. He studied Medicine at The Ohio State University and received executive education at the Wharton School of the University of Pennsylvania and at Harvard Business School (no degrees).